[go: up one dir, main page]

MX357763B - Tratamiento para cancer pancreatico. - Google Patents

Tratamiento para cancer pancreatico.

Info

Publication number
MX357763B
MX357763B MX2016004967A MX2016004967A MX357763B MX 357763 B MX357763 B MX 357763B MX 2016004967 A MX2016004967 A MX 2016004967A MX 2016004967 A MX2016004967 A MX 2016004967A MX 357763 B MX357763 B MX 357763B
Authority
MX
Mexico
Prior art keywords
pancreatic cancer
treatment
administration
treating
subject
Prior art date
Application number
MX2016004967A
Other languages
English (en)
Other versions
MX2016004967A (es
Inventor
W Hedley David
Lohse Ines
M Mason Jacqueline
R Bray Mark
Original Assignee
Univ Health Network
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Health Network filed Critical Univ Health Network
Publication of MX2016004967A publication Critical patent/MX2016004967A/es
Publication of MX357763B publication Critical patent/MX357763B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing alicyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La invención está relacionada con un método para tratar a un sujeto con cáncer pancreático con administración de un compuesto representado por la Fórmula Estructural (I): (ver Fórmula) o una sal farmacéuticamente aceptable del mismo.
MX2016004967A 2013-10-18 2014-10-03 Tratamiento para cancer pancreatico. MX357763B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361892887P 2013-10-18 2013-10-18
PCT/CA2014/050952 WO2015054781A1 (en) 2013-10-18 2014-10-03 Treatment for pancreatic cancer

Publications (2)

Publication Number Publication Date
MX2016004967A MX2016004967A (es) 2016-11-18
MX357763B true MX357763B (es) 2018-07-23

Family

ID=52827497

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016004967A MX357763B (es) 2013-10-18 2014-10-03 Tratamiento para cancer pancreatico.

Country Status (13)

Country Link
US (1) US9642856B2 (es)
EP (1) EP3057593B1 (es)
JP (1) JP6525983B2 (es)
KR (1) KR102195494B1 (es)
CN (1) CN105764515B (es)
AU (1) AU2014336917B2 (es)
CA (1) CA2927612C (es)
EA (1) EA030089B1 (es)
ES (1) ES2908200T3 (es)
IL (1) IL245037B (es)
MX (1) MX357763B (es)
SG (1) SG11201602882VA (es)
WO (1) WO2015054781A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2756568C (en) 2009-04-06 2018-02-13 University Health Network Kinase inhibitors and method of treating cancer with same
ME02545B (me) 2010-04-06 2017-02-20 Univ Health Network Inhibitori kinaza i njihova upotreba u liječenju raka
PT3057965T (pt) 2013-10-18 2019-04-23 Univ Health Network Formas de sal e cristal de inibidor de plk-4
WO2019046949A1 (en) * 2017-09-08 2019-03-14 University Health Network POLYTHERAPIES FOR INHIBITING KINASE 4 OF THE POLO TYPE
CN117794529B (zh) 2021-05-11 2025-02-11 欧瑞克制药公司 Polo样激酶4抑制剂
CN115677682B (zh) * 2021-07-30 2023-07-18 上海齐鲁制药研究中心有限公司 螺环类plk4抑制剂及其用途

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3310891A1 (de) 1983-03-25 1984-09-27 Boehringer Mannheim Gmbh, 6800 Mannheim Neue indolinon-(2)-derivate, verfahren zu ihrer herstellung, diese verbindungen enthaltende arzneimittel und zwischenprodukte
US5182397A (en) 1990-05-31 1993-01-26 American Cyanamid Company Aryloxyspiroalkylindolinone herbicides
GB9507298D0 (en) 1995-04-07 1995-05-31 Pharmacia Spa Substituted indolylmethylene-oxindale analogues as tyrosine kinase inhibitors
US5880141A (en) 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
ES2251741T3 (es) 1996-08-23 2006-05-01 Sugen, Inc. Bibliotecas combinatorias de indolinona y productos afines y metodos para el tratamiento de enfermedades.
GB9716557D0 (en) 1997-08-06 1997-10-08 Glaxo Group Ltd Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
US6133305A (en) 1997-09-26 2000-10-17 Sugen, Inc. 3-(substituted)-2-indolinones compounds and use thereof as inhibitors of protein kinase activity
WO2000008202A2 (en) 1998-08-04 2000-02-17 Sugen, Inc. 3-methylidenyl-2-indolinone modulators of protein kinase
EP1165513A1 (en) 1999-03-24 2002-01-02 Sugen, Inc. Indolinone compounds as kinase inhibitors
YU54202A (sh) 2000-01-18 2006-01-16 Agouron Pharmaceuticals Inc. Jedinjenja indazola, farmaceutske smeše i postupci za stimulisanje i inhibiranje ćelijske proliferacije
EP1294688A2 (en) 2000-06-02 2003-03-26 Sugen, Inc. Indolinone derivatives as protein kinase/phosphatase inhibitors
US6897231B2 (en) 2000-07-31 2005-05-24 Signal Pharmaceuticals, Inc. Indazole derivatives as JNK inhibitors and compositions and methods related thereto
CA2482838A1 (en) 2002-05-31 2003-12-11 Eisai Co., Ltd. Pyrazole compounds and pharmaceutical compositions containing the compound
US7148249B2 (en) 2002-09-12 2006-12-12 Boehringer Ingelheim Pharma Gmbh & Co. Kg Indolinones substituted by heterocycles, the preparation thereof and their use as medicaments
US7205328B2 (en) 2002-10-21 2007-04-17 Irm Llc Oxindoles with anti-HIV activity
WO2005058309A1 (en) 2003-12-16 2005-06-30 Leo Pharma A/S Novel therapeutic use of indolinone derivatives
US7309787B2 (en) 2005-07-13 2007-12-18 Allergan, Inc. Kinase inhibitors
WO2007058626A1 (en) 2005-11-16 2007-05-24 S*Bio Pte Ltd Indazole compounds
US20070135509A1 (en) 2005-12-09 2007-06-14 Blackburn Thomas P Indolone compounds useful to treat cognitive impairment
WO2008001886A1 (fr) * 2006-06-30 2008-01-03 Kyowa Hakko Kirin Co., Ltd. Inhibiteur d'aurora
EP2181108A2 (en) 2007-06-12 2010-05-05 Boehringer Ingelheim International GmbH 3-hetrocyclylidene-indolinone derivatives as inhibitors of specific cell cycle kinases
EP2235004A4 (en) 2007-12-21 2011-05-04 Univ Health Network INDAZOLYL, BENZIMIDAZOLYL, BENZOTRIAZOLYL-SUBSTITUTED INDOLUND DERIVATIVES AS A KINASE-HEMMER FOR CANCER TREATMENT
JP2009173629A (ja) 2007-12-21 2009-08-06 Banyu Pharmaceut Co Ltd Ｒｓｋ１阻害作用を有する新規スピロインダン誘導体
EP2262499B1 (en) 2008-03-11 2016-12-21 University Health Network Mk-0557 for use in the treatment of cancer
EP2108641A1 (en) 2008-04-11 2009-10-14 Laboratorios Almirall, S.A. New substituted spiro[cycloalkyl-1,3'-indo]-2'(1'H)-one derivatives and their use as p38 mitogen-activated kinase inhibitors
EP2113503A1 (en) 2008-04-28 2009-11-04 Laboratorios Almirall, S.A. New substituted indolin-2-one derivatives and their use as p39 mitogen-activated kinase inhibitors
DE102008040187A1 (de) 2008-07-04 2010-01-07 Robert Bosch Gmbh Sensorelement, Verfahren zu seiner Herstellung sowie Verwendung
CA2756568C (en) * 2009-04-06 2018-02-13 University Health Network Kinase inhibitors and method of treating cancer with same
WO2011069298A1 (en) 2009-12-11 2011-06-16 F. Hoffmann-La Roche Ag Novel cyclopropane indolinone derivatives
JP5056876B2 (ja) 2010-03-19 2012-10-24 Ｊｆｅスチール株式会社 冷間加工性と焼入れ性に優れた熱延鋼板およびその製造方法
ME02545B (me) * 2010-04-06 2017-02-20 Univ Health Network Inhibitori kinaza i njihova upotreba u liječenju raka
WO2012000103A1 (en) * 2010-07-02 2012-01-05 University Health Network Methods of targeting pten mutant diseases and compositions therefor
WO2012048411A1 (en) * 2010-10-13 2012-04-19 University Health Network Plk-4 inhibitors and method of treating cancer with same
EP2681216B1 (en) 2011-02-28 2017-09-27 Epizyme, Inc. Substituted 6,5-fused bicyclic heteroaryl compounds
JP7194128B2 (ja) 2017-06-29 2022-12-21 イェンタイ クワンティシジョン ディアグノスティックス インク 固形腫瘍の診断用のバイオマーカーの絶対定量の方法および装置

Also Published As

Publication number Publication date
CN105764515A (zh) 2016-07-13
EP3057593B1 (en) 2021-12-08
US20160250220A1 (en) 2016-09-01
CA2927612A1 (en) 2015-04-23
US9642856B2 (en) 2017-05-09
AU2014336917A1 (en) 2016-05-05
ES2908200T3 (es) 2022-04-28
JP6525983B2 (ja) 2019-06-05
SG11201602882VA (en) 2016-05-30
MX2016004967A (es) 2016-11-18
CN105764515B (zh) 2020-02-28
CA2927612C (en) 2022-08-30
EP3057593A4 (en) 2017-03-08
EA030089B1 (ru) 2018-06-29
IL245037B (en) 2019-06-30
IL245037A0 (en) 2016-05-31
NZ718923A (en) 2021-11-26
WO2015054781A1 (en) 2015-04-23
KR102195494B1 (ko) 2020-12-28
EA201690763A1 (ru) 2016-09-30
KR20160062176A (ko) 2016-06-01
EP3057593A1 (en) 2016-08-24
JP2016533373A (ja) 2016-10-27
AU2014336917B2 (en) 2018-11-29

Similar Documents

Publication Publication Date Title
PH12019501321A1 (en) Methods of treating or preventing cholesterol related disorders
PH12017501016B1 (en) Triazolopyrimidine compounds and uses thereof
PH12018500041A1 (en) Substituted aza compoounds as irak-4 inhibitors
PH12018500981A1 (en) Treatment of osteoarthritis
PH12016502382A1 (en) Substituted indazole compounds as irak4 inhibitors
MD4659B1 (ro) Polimorf al inhibitorilor SYK
PH12019500480A1 (en) Pyridine compound
PH12016500225B1 (en) Novel quinoline-substituted compound
JO3317B1 (ar) مركبات تترا هيدروبيرولو ثيازين
EA201690020A1 (ru) Применение производных пиразолопиридина для лечения рака мочевого пузыря
MX2015011245A (es) Un inhibidor de mdm2 derivado de acido benzoico para el tratamiento del cancer.
EA201491149A1 (ru) Пиразолопиридиновые производные, способы их получения и их терапевтическое применение
MX357763B (es) Tratamiento para cancer pancreatico.
MX2016016388A (es) Uso de compuestos de tienotriazolodiazepina para el tratamiento de cancer de pulmon de celula no pequeña y/o cancer de pulmon de celula pequeña.
MX2015015841A (es) Compuestos de fenoxietil dihidro-1h-isoquinolina.
MX374354B (es) Método de curación de heridas.
NZ728612A (en) Treatment of androgen deprivation therapy associated symptoms
MX358470B (es) Administracion de eritoran o sales farmaceuticamente aceptables del mismo para tratar infecciones para ortomixovirus.
NZ715554A (en) Method of treating hypertrophic cardiomyopathy

Legal Events

Date Code Title Description
FG Grant or registration